Biomerica, Inc., a leading biomedical technology company, has been making significant strides in the development, patenting, manufacturing, and marketing of innovative diagnostic and therapeutic products for medical conditions and diseases worldwide. The company's outstanding diagnostic test kits have been designed to effectively analyze blood, urine, nasal, or fecal specimens from patients, thereby facilitating the diagnosis of various diseases, medical complications, and food intolerances. Biomerica's products also promote the measurement of hormones, bacteria, antibodies, antigens, and other substances that may exist in the human body, blood, or stools in minute concentrations. In terms of its product line, the company concentrates primarily on gastrointestinal diseases, food intolerances, and various esoteric tests for use at physicians' offices, over-the-counter drugstores, and hospital/clinical laboratories. Biomerica is also working on groundbreaking projects such as InFoods, which utilizes a simple blood sample to identify patient-specific foods that may alleviate irritable bowel syndrome symptoms. Additionally, it is developing a Helicobacter pylori test that indicates whether a patient is infected with the H. Pylori bacteria. Moreover, Biomerica is working on developing products that detect COVID-19 infections in individuals. Its extensive research and development efforts in the area of COVID-19 detection have positioned the company as a leading player in the fight against the pandemic. Founded in 1971, Biomerica is headquartered in Irvine, California. Its innovative products and services have been recognized worldwide and have earned the company a solid reputation in the biomedical technology industry.